Insider Buying: Enovis (NYSE:ENOV) Insider Acquires 2,468 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider John Kleckner purchased 2,468 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was acquired at an average cost of $30.32 per share, with a total value of $74,829.76. Following the transaction, the insider directly owned 12,302 shares in the company, valued at $372,996.64. This trade represents a 25.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Enovis Stock Down 0.1%

NYSE ENOV traded down $0.04 on Friday, hitting $30.27. 236,231 shares of the stock were exchanged, compared to its average volume of 1,083,747. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The company has a 50-day moving average price of $30.74 and a 200-day moving average price of $31.02. The company has a market cap of $1.73 billion, a PE ratio of -2.12 and a beta of 1.67. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.75.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share for the quarter. The business had revenue of $383.81 million during the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. Sell-side analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on ENOV shares. Needham & Company LLC reduced their target price on shares of Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. UBS Group cut their price target on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a report on Friday, August 8th. Wells Fargo & Company raised their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group cut their target price on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.17.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ENOV. Danske Bank A S acquired a new stake in shares of Enovis in the third quarter valued at about $64,000. Verition Fund Management LLC boosted its holdings in Enovis by 22.4% in the 3rd quarter. Verition Fund Management LLC now owns 55,066 shares of the company’s stock worth $1,671,000 after acquiring an additional 10,060 shares during the period. Millennium Management LLC grew its position in Enovis by 90.8% in the third quarter. Millennium Management LLC now owns 336,339 shares of the company’s stock valued at $10,205,000 after acquiring an additional 160,060 shares in the last quarter. London Co. of Virginia raised its stake in shares of Enovis by 2.3% during the third quarter. London Co. of Virginia now owns 457,836 shares of the company’s stock valued at $13,891,000 after purchasing an additional 10,460 shares during the period. Finally, Invenomic Capital Management LP boosted its stake in shares of Enovis by 22.7% in the third quarter. Invenomic Capital Management LP now owns 712,669 shares of the company’s stock valued at $21,622,000 after purchasing an additional 131,705 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.